Literature DB >> 3072777

Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors.

W Lawrence, D M Hays, R Heyn, M Beltangady, H M Maurer.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3072777     DOI： 10.1007/bf01655884

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  11 in total

1.  EMBRYONAL RHABDOMYOSARCOMA. A CLINICOPATHOLOGICAL STUDY.

Authors:  W LAWRENCE; G JEGGE; F W FOOTE
Journal:  Cancer       Date:  1964-03       Impact factor: 6.860

2.  Embrynal rhabdomyosarcoma of the head and neck.

Authors:  O MOORE; C GROSSI
Journal:  Cancer       Date:  1959 Jan-Feb       Impact factor: 6.860

3.  The intergroup rhabdomyosarcoma study: a preliminary report.

Authors:  H M Maurer; T Moon; M Donaldson; C Fernandez; E A Gehan; D Hammond; D M Hays; W Lawrence; W Newton; A Ragab; B Raney; E H Soule; W W Sutow; M Tefft
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

4.  The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children.

Authors:  R M Heyn; R Holland; W A Newton; M Tefft; N Breslow; J R Hartmann
Journal:  Cancer       Date:  1974-12       Impact factor: 6.860

5.  The rationale for planned reoperation after unplanned total excision of soft-tissue sarcomas.

Authors:  A E Giuliano; F R Eilber
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

6.  Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II).

Authors:  W Lawrence; E A Gehan; D M Hays; M Beltangady; H M Maurer
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

7.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

8.  Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study.

Authors:  W Lawrence; D M Hays; R Heyn; M Tefft; W Crist; M Beltangady; W Newton; M Wharam
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

9.  Prognostic factors in children with rhabdomyosarcoma.

Authors:  E A Gehan; F N Glover; H M Maurer; W W Sutow; D M Hays; W Lawrence; W A Newton; E H Soule
Journal:  Natl Cancer Inst Monogr       Date:  1981-04

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  4 in total

1.  Soft-tissue sarcomas of the extremities in patients of pediatric age.

Authors:  Michela Casanova; Cristina Meazza; Alessandro Gronchi; Marco Fiore; Elena Zaffignani; Marta Podda; Paola Collini; Lorenza Gandola; Andrea Ferrari
Journal:  J Child Orthop       Date:  2007-09-01       Impact factor: 1.548

Review 2.  MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality.

Authors:  Rossella Rota; Roberta Ciarapica; Antonio Giordano; Lucio Miele; Franco Locatelli
Journal:  Mol Cancer       Date:  2011-09-24       Impact factor: 27.401

3.  Surgical Principles for Children/Adolescents With Newly Diagnosed Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David A Rodeberg; Charles N Paidas; Thom L Lobe; Kenneth Brown; Richard J Andrassy; William M Crist; Eugene S Wiener
Journal:  Sarcoma       Date:  2002

4.  The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

Authors:  R B Raney; H M Maurer; J R Anderson; R J Andrassy; S S Donaldson; S J Qualman; M D Wharam; E S Wiener; W M Crist
Journal:  Sarcoma       Date:  2001
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.